

Ref: FOI/GS/ID 9513

**Please reply to:**  
FOI Administrator  
Trust Management  
Maidstone Hospital  
Hermitage Lane  
Maidstone, Kent  
ME16 9QQ  
Email: [mtw-tr.foiadmin@nhs.net](mailto:mtw-tr.foiadmin@nhs.net)  
[www.mtw.nhs.uk](http://www.mtw.nhs.uk)

22 November 2024

## **Freedom of Information Act 2000**

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to multiple myeloma [MM].

*You asked: All questions are shown as received by the Trust.*

*Q1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.*

*Q2. Of the multiple myeloma patients over the past 6 month, how many were treated with the following:*

- a. Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd)*
- b. Bortezomib, thalidomide and dexamethasone [VTD]*
- c. Daratumumab [Darzalex] with Lenalidomide [Revlimid] and dexamethasone*
- d. Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd)*
- e. Selinexor, Bortezomib [Velcade] and dexamethasone*
- f. Carfilzomib [Kyprolis] and dexamethasone*
- g. Bortezomib [Velcade] monotherapy or with dexamethasone*
- h. Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd)*
- i. Carfilzomib [Kyprolis], Lenalidomide [Revlimid] and dexamethasone*
- j. Belantamab Mafodotin [Blenrep]*
- k. Idecabtagene vicleucel [Abecma]*
- l. Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd)*
- m. Elranatamab*
- n. Daratumumab [Darzalex] monotherapy*
- o. Ixazomib [Ninlaro], Lenalidomide [Revlimid] and dexamethasone (known as IRd)*

- p. *Lenalidomide [Revlimid] and dexamethasone*
- q. *Lenalidomide [Revlimid] monotherapy*
- r. *Pomalidomide [Imnovid] and dexamethasone*
- s. *Selinexor and dexamethasone*
- t. *Talquetamab*
- u. *Teclistamab [Tecvayli]*
- v. *Any other systemic anti-cancer therapy*

Trust response:

- 1. 87
- 2.
- a. 0
- b. 0
- c. 19
- d. 12
- e. 1
- f. 0
- g. 8
- h. 12
- i. 3
- j. 0
- k. 0
- l. 8
- m. 5
- n. 20
- o. 12
- p. 0
- q. 45
- r. 4
- s. 0
- t. 1
- u. 0
- v. 11